Targets › TCEA1
1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout Dec 2026.
Necessary for efficient RNA polymerase II transcription elongation past template-encoded arresting sites. The arresting sites in DNA have the property of trapping a certain fraction of elongating RNA polymerases that pass through, resulting in locked ternary complexes. (UniProt, P23193)
Open in Phaseline: the race on TCEA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Instituto Mexicano del Seguro Social | DTG/3TC Dolutegravir (integrase strand transfer inhibitor) and lamivudine (nucleoside reverse tran | INTEGRASE, TCEA1 | Phase 4 | HIV Infection | Dec 2026 |
HIV Infection (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.